CLBS - Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
- Caladrius Biosciences press release ( NASDAQ: CLBS ): Q2 GAAP EPS of -$0.11 beats by $0.01 .
- As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million.
- Merger with Cend Therapeutics remains on track to close in Q3.
For further details see:
Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01